2025 first_quarter Filing

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act.

H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.

Issues related to tax reform. Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation. Issues related to R&D tax credit.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Issues related to pharmaceutical IP, supply chain, and tariffs.